Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-103 in adults with classical PKU
NCT05222178Phase 1Terminated
- Sponsor
- Homology Medicines
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Gene Silencing, CRISPR-Cas9, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of HMI-103 in Phenylketonuria (PKU) (3 cohorts), sponsored by Homology Medicines. Primary endpoints: Treatment Emergent Adverse Events and Reduction of plasma Phe concentration. Started Jun 2022; status: terminated.
02
Drugs
HMI-103
03
Conditions
Phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05222178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222178.